Chapter 18. Methods for Monitoring of the Anti-Angiogenic Activity of Agents in Patients: Novel Trial Design

  1. Carolyn A. Staton3,4,
  2. Claire Lewis5 and
  3. Roy Bicknell6
  1. Shannon Smiley1,
  2. Michael K. K. Wong1 and
  3. Shaker A. Mousa2

Published Online: 27 SEP 2007

DOI: 10.1002/9780470029350.ch18

Angiogenesis Assays: A Critical Appraisal of Current Techniques

Angiogenesis Assays: A Critical Appraisal of Current Techniques

How to Cite

Smiley, S., Wong, M. K. K. and Mousa, S. A. (2006) Methods for Monitoring of the Anti-Angiogenic Activity of Agents in Patients: Novel Trial Design, in Angiogenesis Assays: A Critical Appraisal of Current Techniques (eds C. A. Staton, C. Lewis and R. Bicknell), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9780470029350.ch18

Editor Information

  1. 3

    Academic Unit of Surgical Oncology, University of Sheffield Medical School, Sheffield, UK

  2. 4

    Academic Unit of Surgical Oncology, K-Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK

  3. 5

    Academic Unit of Pathology, University of Sheffield Medical School, Sheffield, UK

  4. 6

    Division of Immunity and Infection, University of Birmingham, Birmingham, UK

Author Information

  1. 1

    Roswell Park Cancer Institute, Elm and Carlton Sreets, Buffalo, New York 14263, USA

  2. 2

    Pharmaceutical Research Institute at Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA

Publication History

  1. Published Online: 27 SEP 2007
  2. Published Print: 15 DEC 2006

ISBN Information

Print ISBN: 9780470016008

Online ISBN: 9780470029350

SEARCH

Keywords:

  • angiogenesis modulation;
  • anti-angiogenesis;
  • tumour angiogenesis target in anticancer therapy;
  • tumour micro-environmental factors;
  • platelets and angiogenesis;
  • monitoring clinical trials;
  • microvessel density;
  • Dynamic contrast enhanced MRI (DCE-MRI)

Summary

This chapter contains sections titled:

  • Introduction

  • Tumour micro-environmental factors

  • Possible mechanisms of acquired resistance to anti-angiogenic drugs

  • Standard chemotherapy versus angiogenesis inhibitors

  • Monitoring clinical trials

  • Tumour dormancy and tumour progression

  • Tumour markers

  • Microvessel density

  • Surrogate endpoints

  • Molecular imaging

  • New insights into trial design

  • Concluding remarks

  • References